Mirapex

This MedLibrary.org supplementary page on Mirapex is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Pramipexole
Systematic (IUPAC) name
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
Identifiers
CAS number 104632-26-0
ATC code N04BC05
PubChem 59868
DrugBank APRD00156
Chemical data
Formula C10H17N3S 
Mol. mass 211.324 g/mol
Pharmacokinetic data
Bioavailability >90%
Protein binding 15%
Metabolism Minimal
Half life 8 hours
Excretion Renal (90%) and fecal (2%)
Therapeutic considerations
Licence data

EU, US
Pregnancy cat.

B3(AU) C(US)
Legal status

℞ Prescription only
Routes Oral

Pramipexole (INN, trade names Mirapex and Sifrol) is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder[1]. Pramipexole is classified as a non-ergoline dopamine agonist.

Contents

Mechanism of action

Basal ganglia connectivity diagram showing glutamatergic pathways as red, dopaminergic as magenta and GABA pathways as blue.
Basal ganglia connectivity diagram showing glutamatergic pathways as red, dopaminergic as magenta and GABA pathways as blue.

The basal ganglia is a region of the human brain involved in the regulation of body movement; hence, when components of the basal ganglia are damaged, disorders of body movement may occur.

Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are neurons that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired.

By acting as an agonist to the dopamine receptors, pramipexole may directly stimulate dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia. Any depressant effects are most likely the result of pramipexole binding to the D2 receptor subtype, which exhibits inhibitory behavior.

Pramipexole binds to dopamine receptors, with particularly high affinity for the D3 receptor subtype.[2]

Adverse effects

Some of the more common side effects of pramipexole include:[3]

  • Dizziness, lightheadedness, or fainting, especially when standing up (orthostatic hypotension)
  • Drowsiness
  • Hallucinations (seeing, hearing, or feeling things that are not there)
  • Weight gain
  • Weight loss
  • Nausea
  • Trouble in sleeping
  • Twitching, twisting, or other unusual body movements
  • Unusual tiredness or weakness

Several unusual adverse effects of this medication may include compulsive gambling, hypersexuality, and overeating. These side effects may be linked to the D3 receptor agonist activity of pramipexole. D3 receptors are located in brain regions involved in mood, behavior, and rewards.[4]

References

Notes

  1. ^ Biol Psychiatry. 2004 Jul 1;56(1):54-60. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK.PMID: 15219473
  2. ^ Mierau J, Schneider F, Ensinger H, Chio C, Lajiness M, Huff R (1995). "Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.". Eur J Pharmacol 290 (1): 29–36. doi:10.1016/0922-4106(95)90013-6. PMID 7664822. 
  3. ^ "MedlinePlus Drug Information: Pramipexole (Systemic)". United States National Library of Medicine. Retrieved on 2006-09-27.
  4. ^ Mayo Clinic Staff; M. Leann Dodd (July 15, 2005). "Parkinson's drug can cause compulsive gambling". Mayo Clinic. Retrieved on 2006-09-27.

Sources

External links

v • d • e
Antiparkinson drugs: dopaminergic agents (N04B)
Dopa and derivatives
Adamantane derivatives
Dopamine agonists
MAOIs (B)
COMT inhibitors
Other

Wikipedia content modification information:

  • This page was last modified on 10 July 2008, at 01:52.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Mirapex".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.